← Oncology Approval Tracker

FDA DECISION ·

Fruzaqla

fruquintinib · Takeda Pharmaceuticals

FDA approvalNew therapyColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin and irinotecan regimens and anti-VEGF therapy. Patients with RAS wild-type disease should have received anti-EGFR therapy if medically appropriate.

LAMPGEN ANALYSIS

Why it matters

This decision introduced a later-line targeted option after several established systemic therapies.

What research teams should watch

Audit prior regimens, RAS testing and the rationale when anti-EGFR treatment was medically inappropriate.

PRIMARY RECORDS

Sources